文献速递青光眼

TVT IRIS登记研究1年复合结局分析及与随机对照试验的比较

Tube Versus Trabeculectomy IRISⓇ Registry 1-Year Composite Outcome Analysis with Comparisons to the Randomized Controlled Trial.
PubMed 文献 · Am J Ophthalmol · 2021-02-28

本研究比较了TVT随机对照试验(RCT)的1年复合治疗结局与IRIS登记中类似眼的结果。IRIS队列包含419眼(管植入236眼,小梁切除术183眼),管植入眼失败风险12.3%,小梁切除术眼16.4%,差异无统计学意义(P=0.231)。但IRIS登记中管植入眼的失败风险显著高于TVT RCT中的管植入眼(3.8%;P<.001)。

要点

  • IRIS登记中管植入与小梁切除术后1年复合失败风险无显著差异。
  • IRIS登记管植入眼失败风险显著高于TVT RCT管植入眼。
  • 失败原因包括青光眼再手术,而TVT RCT 1年时无再手术。

核心结论

  • IRIS登记队列中管植入眼与小梁切除术眼的1年复合失败风险无显著差异。
  • IRIS登记管植入眼的失败风险显著高于TVT RCT管植入眼。

研究设计与样本

  • 回顾性临床研究,将IRIS登记中既往接受过小梁切除术和/或白内障摘除后行管植入或小梁切除术且有一年随访数据的眼与TVT RCT进行比较。

主要发现

  • TVT IRIS登记队列共419眼,其中管植入236眼(56.3%),小梁切除术183眼(43.7%)。
  • 该队列中管植入眼失败风险12.3%,小梁切除术眼16.4%,差异无统计学意义(P=0.231)。
  • 与TVT RCT相比,IRIS登记管植入眼失败风险显著更高(TVT RCT管植入眼为3.8%;P<.001)。
  • 治疗失败原因包括因青光眼再手术,而TVT RCT 1年时无再手术。

关键数值与推荐

  • 失败定义:术后3个月后连续两次随访出现低眼压(眼压≤5 mm Hg)或眼压控制不佳(眼压>21 mm Hg或较基线降低不足20%)、因青光眼再手术或无光感。

临床怎么用

  • 真实世界IRIS登记中管植入眼1年失败风险高于TVT RCT,提示临床决策需考虑非Baerveldt管、更严重眼别及实践模式差异。

局限性

  • 结果与TVT RCT不同,可能原因包括非Baerveldt管、管植入眼病情更严重以及反映真实世界数据的实践模式与RCT不同。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study compared 1-year results for the composite treatment outcome from the Tube Versus Trabeculectomy (TVT) randomized controlled trial (RCT) to those from an IRISⓇ (Intelligent Research In Sight) Registry cohort of analogous eyes. DESIGN: Retrospective clinical study with comparison to an RCT. METHODS: Subjects' eyes in the IRIS Registry received either a glaucoma drainage implant (tube) or underwent trabeculectomy after a previous trabeculectomy and/or cataract extraction and had data for 1-year follow-up analyses. OUTCOME: Eyes were classified as failing if they had hypotony (intraocular pressure (IOP) ≤5 mm Hg) or inadequate IOP control (IOP >21 mm Hg or not reduced at least 20% below baseline) on 2 consecutive follow-up visits after 3 months, a reoperation for glaucoma, or no light perception vision and as successful otherwise. Failure risk was compared by treatment, demographic, and clinical variables and was compared to analogous failure risks from the TVT RCT. RESULTS: The TVT IRIS Registry cohort included 419 eyes, 236 tube eyes (56.3%) and 183 trabeculectomy eyes (43.7%). In this cohort, there was no significant failure risk difference (12.3% for tube eyes and 16.4% for trabeculectomy eyes, P = 0.231). Comparing the studies, there was a significantly greater risk of failure in the TVT IRIS Registry tube eyes than in the TVT RCT tube eyes (3.8%; P <.001). Reasons for treatment failure included reoperations for glaucoma (none in the TVT RCT at 1 year). CONCLUSIONS: Our results were different from those in the TVT RCT. Possible reasons include non-Baerveldt tubes, greater severity among tube eyes, and practice patterns that reflect real-world data, which are different than those in RCTs.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Vanner EA, Sun CQ, McSoley MJ, et al. Tube Versus Trabeculectomy IRISⓇ Registry 1-Year Composite Outcome Analysis with Comparisons to the Randomized Controlled Trial. Am J Ophthalmol. 2021. PMID: 33657420. doi:10.1016/j.ajo.2021.02.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。